Targeting the antigen-binding site of HLA-restricting alleles in treatment of autoimmune disease

Critical Reviews in Immunology

Volumn 27, Issue 3, 2007, Pages 271-288

  Oshima, Minako ^a   Deitiker, Philip ^a   Atassi, M Zouhair ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Acetylcholine receptor; Antibodies; Antigen presentation; Autoimmune disease; Immunotherapy; MHC; Myasthenia gravis; Synthetic peptides

Indexed keywords

ACETYLCHOLINE RECEPTOR ALPHA; ACETYLCHOLINE RECEPTOR I AB BETA[62-76]; AUTOANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; HLA DQB1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ALLELE; AMINO ACID SEQUENCE; ANTIBODY COMBINING SITE; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CONFERENCE PAPER; DISEASE MODEL; HAPLOTYPE; HLA SYSTEM; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MYASTHENIA GRAVIS; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; T LYMPHOCYTE;

EID: 38049084108     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevimmunol.v27.i3.60     Document Type: Conference Paper

References (80)

1. Donaldson DH, Ansher M, Horan S, Rutherford RB, Ringel SP. The relationship of age to outcome in myasthenia gravis. Neurology. 1990;40:786-90.
2. Roost HP, Charan S, Zinkernagel RM. Analysis of the kinetics of antiviral memory T help in vivo: characterization of short-lived cross-reactive T help. Eur J Immunol. 1990;20:2547-54.
3. Gray D, Matzinger P. T cell memory is short-lived in the absence of antigen. J Exp Med. 1991;174:969-74.
4. Adorini L, Guery JC, Rodriguez-Tarduchy G, Trembleau S. Selective immunosuppression. Immunol Today. 1993;14:285-9.
5. Yasunaga S, Kimura A, Hamaguchi K, Ronningen KS, Sasazuki T. Different contribution of HLA-DR and -DQ genes in susceptibility and resistance to insulin-dependent diabetes mellitus (IDDM). Tissue Antigens. 1996;47:37-48.
6. Kaufman JF, Strominger JL. HLA-DR light chain has a polymorphic N-terminal region and a conserved immunoglobulin-like C-terminal region. Nature. 1982;297:694-7.
7. Appel SH, Almon RR, Levy N. Acetylcholine receptor antibodies in myasthenia gravis. N Engl J Med. 1975;293:760-1.
8. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26:1054-9.
9. Hohlfeld R, Kalies I, Kohleisen B, Heininger K, Conti-Tronconi B, Toyka KV. Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines. Neurology. 1986;36:618-21.
10. Oshima M, Ashizawa T, Pollack MS, Atassi MZ. Autoimmune T cell recognition of human acetylcholine receptor: the sites of T cell recognition in myasthenia gravis on the extracellular part of the α subunit. Eur J Immunol. 1990;20:2563-9.
11. Ofosu-Appiah W, Mokhtarian F, Shirazian D, Grob D. Production of anti-acetylcholine receptor-α antibody in vitro by peripheral blood lymphocytes of patients with myasthenia gravis: role of immunoregulatory T cells and monocytes. J Lab Clin Med. 1994;124:231-41.
12. Rosenberg JS, Oshima M, Atassi MZ. B-cell activation in vitro by helper T cells specific to region α146-162 of Torpedo californica nicotinic acetylcholine receptor. J Immunol. 1996;157:3192-9.
13. Oshima M, Atassi MZ. T cells of mice treated with mPEG-myasthenogenic peptide conjugate are involved in protection against EAMG by stimulating lower pathogenic antibody responses. Autoimmunity. 2000;32:45-55.
14. Bell J, Rassenti L, Smoot S, Smith K, Newby C, Hohlfeld R, Toyka K, McDevitt H, Steinman L. HLA-DQ beta-chain polymorphism linked to myasthenia gravis. Lancet. 1986;i:1058-60.
15. Garchon HJ. Genetics of autoimmune myasthenia gravis, a model for antibody-mediated autoimmunity in man. J Autoimmun. 2003;21:105-10.
16. Matsuki K, Juji T, Tokunaga K, Takamizawa M, Maeda H, Soda M, Nomura Y, Segawa M. HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest. 1990;86:392-9.
17. Hjelmstrom P, Peacock CS, Giscombe R, Pirskanen R, Lefvert AK, Blackwell JM, Sanjeevi CB. Myasthenia gravis with thymic hyperplasia is associated with polymorphisms in the tumor necrosis factor region. Ann N Y Acad Sci. 1998;841:368-70.
18. Horiki T, Inoko H, Moriuchi J, Ichikawa Y, Arimori S. Combinations of HLA-DPB1 and HLA-DQB1 alleles determine susceptibility to early-onset myasthenia gravis in Japan. Autoimmunity. 1994;19:49-54.
19. Nagvekar N, Corlett L, Jacobson LW, Matsuo H, Chalkley R, Driscoll PC, Deshpande S, Spack EG, Willcox N. Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: overlapping natural and artificial determinants in the human acetylcholine receptor. J Immunol. 1999;162:4079-87.
20. Kanai T, Nomura Y, Segawa M, Takagi K, Senju S, Matsushita S, Nishimura Y. Immuno-suppressive peptides for a human T cell clone autoreactive to a unique acetylcholine receptor alpha subunit peptide presented by the disease-susceptible HLA-DQ6 in infant-onset myasthenia gravis. Hum Immunol. 1997;56:28-38.
21. Zhang Y, Schleup M, Frutiger S, Hughes GJ, Jeannet M, Steck A, Barkas T. Immunological heterogeneity of autoreactive T lymphocytes against the nicotinic acetylcholine receptor in myasthenia patients. Eur J Immunol. 1990;20:2577-83.
22. Christadoss P, Lennon VA, Krco CJ, David CS. Genetic control of experimental autoimmune myasthenia gravis in mice. III. Ia molecules mediate cellular immune responsiveness to acetylcholine receptors. J Immunol. 1982;128:1141-4.
23. Christadoss P, Lindstrom JM, Melvold RW, Talal N. Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis. Immunogenetics. 1985;21:33-8.
24. bm12: a new H-2 mutation in the I region in the mouse. J Exp Med. 1979;150:1323-38.
25. McIntyre KR, Seidman JG. Nucleotide sequence of mutant I-Aβbm12 gene is evidence for genetic exchange between mouse immune response genes. Nature. 1984;308:551-3.
26. Karlin A. Molecular properties of nicotinic acetylcholine receptors. In: Colman CW, Poste G, Nicolson GL, editors. Cell surface and neuronal function. New York: Elsevier/North Holland Biomedical Press; 1980. p. 191-260.
27. Changeux JP, Devillers-Thiery A, Chemouilli P. Acetylcholine receptor: an allosteric protein. Science. 1984;225:1335-45.
28. Sobel A, Weber M, Changeux JP. Large-scale purification of the acetylcholine-receptor protein in its membrane-bound and detergent-extracted forms from Torpedo marmorata electric organ. Eur J Biochem. 1977;80:215-24.
29. Tzartos SJ, Changeux JP. High affinity binding of alpha-bungarotoxin to the purified alpha-subunit and to its 27,000-dalton proteolytic peptide from Torpedo marmorata acetylcholine receptor. Requirement for sodium dodecyl sulfate. EMBO J. 1983;2:381-7.
30. McCormick DJ, Atassi MZ. Localization and synthesis of the acetylcholine-binding site in the α-chain of the Torpedo californica acetylcholine receptor. Biochem J. 1984;224:995-1000.
31. Hohlfeld R, Toyka KV, Tzartoss SJ, Carson W, Conti-Tronconi B. Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor α subunit. Proc Natl Acad Sci U S A. 1987;84:5379-83.
32. Lennon VA, Lambert ED, Leiby KR, Okarma TB, Talib S. Recombinant human acetylcholine receptor α-subunit induces chronic experimental autoimmune myasthenia gravis. J Immunol. 1991;146:2245-8.
33. Lennon VA, McCormick DJ, Lambert EH, Griesmann GE, Atassi MZ. Region of peptide 125-147 of acetylcholine receptor α subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies. Proc Natl Acad Sci U S A. 1985;82:8805-9.
34. Kazim AL, Atassi MZ. A novel and comprehensive synthetic approach for the elucidation of protein antigenic structures. Determination of the full antigenic profile of the α-chain of human haemoglobin. Biochem J. 1980;191:261-4.
35. Noda M, Furutani Y, Takahashi H, Toyosato M, Tanabe T, Shimizu S, Kikyotani S, Kayano T, Hirose T, Inayama S, Numa S. Cloning and sequence analysis of calf cDNA and human genomic DNA encoding α-subunit precursor of muscle acetylcholine receptor. Nature. 1983;305:818-23.
36. Noda M, Takahashi H, Tanabe T, Toyosato M, Furutani Y, Hirose T, Asai M, Inayama S, Miyata T, Numa S. Primary structure of α-subunit precursor of Torpedo californica acetylcholine receptor deduced from cDNA sequence. Nature. 1982;299:793-7.
37. Oshima M, Pachner AR, Atassi MZ. Profile of the regions of acetylcholine receptor α chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor. Mol Immunol. 1994;31:833-43.
38. Yokoi T, Mulac-Jericevic B, Kurisaki J, Atassi MZ. T lymphocyte recognition of acetylcholine receptor: Localization of the full T-cell recognition profile on the extracellular part of the α chain of Torpedo californica acetylcholine receptor. Eur J Immunol. 1987;17:1697-702.
39. Pachner AR, Kantor FS, Mulac-Jericevic B, Atassi MZ. An immunodominant site of acetylcholine receptor in experimental myasthenia gravis mapped with T-lymphocyte clones and synthetic peptides. Immunol Lett. 1989;20:199-204.
40. Ashizawa T, Ruan KH, Jinnai K, Atassi MZ. Profile of the regions on the alpha-chain of human acetylcholine receptor recognized by autoantibodies in myasthenia gravis. Mol Immunol. 1992;29:1507-14.
41. Oshima M, Deitiker PR, Mosier DR, Smith RG, Atassi MZ. Responses in vitro of peripheral blood lymphocytes from patients with myasthenia gravis to stimulation with human AChR α-chain peptides: analysis in relation to age, thymic abnormality and ethnicity. Hum Immunol. 2005;66:32-42.
42. Isenberg KE, Mudd J, Shah V, Merlie JP. Nucleotide sequence of the mouse muscle nicotinic acetylcholine receptor α subunit. Nucleic Acids Res. 1986;14:5111.
43. Mulac-Jericevic B, Atassi MZ. Profile of the α-bungarotoxin-binding regions on the extracellular part of the α-cahin of Torpedo californica acetylcholine receptor. Biochem J. 1987;248:847-52.
44. Atassi MZ, Ruan KH, Jinnai K, Oshima M, Ashizawa T. Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide. Proc Natl Acad Sci U S A. 1992;89:5852-6.
45. bm12 mutation, which confers resistance to experimental myasthenia gravis, drastically affects the epitope repertoire of murine CD4+ cells sensitized to nicotinic acetylcholine receptor. J Immunol. 1991;147:1484-91.
46. Infante AJ, Thompson PA, Krolick KA, Wall KA. Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes. J Immunol. 1991;146:2977-82.
47. Shenoy M, Oshima M, Atassi MZ, Christadoss P. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region α146-162 of acetylcholine receptor. Clin Immunol Immunopath. 1993;66:230-8.
48. Shenoy M, Goluszko E, Christadoss P. The pathogenic role of acetylcholine receptor α chain epitope within α146-162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice. Clin Immunol Immunopathol. 1994;73:338-43.
49. Atassi MZ, Oshima M. Autoimmune responses against acetylcholine receptor: T and B cell collabora-tion and manipulation by synthetic peptides. Crit Rev Immunol. 1997;17:481-95.
50. Deitiker P, Ashizawa T, Atassi MZ. Antigen mimicry in autoimmune disease. Can immune responses to microbial antigens that mimic acetylcholine receptor act as initial triggers of Myasthenia gravis? Hum Immunol. 2000;61:255-65.
51. Atassi MZ, Oshima M, Deitiker P. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope. Crit Rev Immunol. 2001;21:1-27.
52. Deitiker PR, Oshima M, Smith RG, Mosier DR, Atassi MZ. Subtle differences in HLA DQ haplotype-associated presentation of AChR α-chain peptides may suffice to mediate myasthenia gravis. Autoimmunity. 2006;39:277-88.
53. b on binding with and antigen presentation of Torpedo acetylcholine receptor α chain peptide 146-162. J Immunol. 1995;154:5245-54.
54. Nakayashiki N, Oshima M, Deitiker PR, Ashizawa T, Atassi MZ. Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic Tcell epitope. J Neuroimmunol. 2000;105:131-44.
55. Estess P, Begovich AB, Koo M, Jones PP, McDevitt HO. Sequence analysis and structure-function correlations of murine q, k, u, s, and f haplotype I-Aβ cDNA clones. Proc Natl Acad Sci U S A. 1986;83: 3594-8.
56. Oshima M, Deitiker P, Ashizawa T, Atassi MZ. Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG. Autoimmunity. 2002:35:183-90.
57. Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today. 1993;14:281-4.
58. Boughton CR. Pertussis vaccines: acellular versus whole-cell. Med J Aust. 1996;164:564-6.
59. Oshima M, Maruta T, Ohtani M, Deitiker PR, Mosier DR, Atassi MZ. Vaccination with a MHC class II peptide in Alum and inactive pertussis strongly ameliorates clinical MG in C57BL/6 mice. J Neuroimmunol. 2006;171:8-16.
60. Khalil I, Berrih-Aknin S, Lepage V, Loste MN, Gajdos P, Hors J, Charron D, Degos L. Trans-encoded DQ alpha beta heterodimers confer susceptibility to myasthenia gravis disease. C R Acad Sci III. 1993;316:652-60.
61. Shinomiya N, Nomura Y, Segawa M. A variant of childhood-onset myasthenia gravis: HLA typing and clinical characteristics in Japan. Clin Immunol. 2004;110:154-8.
62. Hjelmstrom P, Giscombe R, Lefvert AK, Pirskanen R, Kockum I, Landin-Olsson M, Sanjeevi CB. Different HLA-DQ are positively and negatively associated in Swedish patients with myasthenia gravis. Autoimmunity. 1995;22:59-65.
63. Vieira ML, Caillat-Zucman S, Gajdos P, Cohen-Kaminsky S, Casteur A, Bach JF. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J Neuroimmunol. 1993;47:115-22.
64. Baggi F, Antozzi C, Andreetta F, Confaloniri P, Ciusani E, Begovich AB, Erlich HA, Cornelio A, Mantegazza R. Identification of a novel HLA class II association with DQB1*0502 in an Italian myasthenic population. Ann N Y Acad Sci. 1998;841:355-9.
65. Spurkland A, Gilhus NE, Ronningen KS, Aarli JA, Vartdal F. Myasthenia gravis patients with thymus hyperplasia and myasthenia gravis patients with thymoma display different HLA associations. Tissue Antigens. 1991;37:90-3.
66. Hjelmstrom P, Giscombe R, Lefvert AK, Pirskanen R, Kockum I, Landin-Olsson M, Sanjeevi CB. Polymorphic amino acid domains of the HLA-DQ molecules are associated with disease heterogeneity in myasthenia gravis. J Neuroimmunol. 1996;65:125-31.
67. Suzuki S, Kuwana M, Yasuoka H, Tanaka K, Fukuuchi Y, Kawakami Y. Heterogeneous immunogenetic background in Japanese adults with myasthenia gravis. J Neurol Sci. 2001;189:59-64.
68. Garcia-Ramos G, Tellez-Zenteno JF, Zapata-Zuniga M, Yamamoto-Furusho JK. Ruiz-Morales JA., Villarreal-Garza C, Vargas-Alarcon G, Estanol B, Llorente L, Granados J. HLA class II genotypes in Mexican Mestizo patients with myasthenia gravis. Eur J Neurology. 2003;10:707-10.
69. Fernandez-Mestre MT, Vargas,V, Montagnani S, Cotua M, Ogando V, Layrisse Z. HLA class II and class I polymorphism in Venezuelan patients with myasthenia gravis. Hum Immunol. 2004;65:54-9.
70. Todd JA, Acha-Orbea H, Bell JL, Chao N, Fronek Z, Jacob CO, McDermott M, Sinh AA, Timmerman L, Steinman L, McDevitt HO. A molecular basis for MHC class II-associated autoimmunity. Science. 1988;240:1003-9.
71. Bugawan TL, Angelini G, Larrick J, Auricchio S, Ferrarar GB, Erlich HA. A combination of a particular HLA-DP β allele and an HLA-DQ heterodimer confers susceptibility to coeliac disease. Nature. 1989;339:470-3.
72. Ong B, Willcox N, Wordsworth P, Beeson D, Vincent A, Altmann D, Lanchbury JSS, Harcourt GC, Bell JI, Newsom-Davis J. Critical role for the Val/Gly86 HLA-DRb dimorphism in autoantigen presentation to human T cells. Proc Natl Acad Sci U S A. 1991;88:7343-7.
73. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban G, Strominger JL, Wiley DC. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 1994;368:215-21.
74. Oshima M, Ohtani M, Deitiker PR, Smith RG, Mosier DR, Atassi MZ. Suppression by mAbs against DQB1 peptides of in vitro proliferation of AChR-specific T cells from myasthenia gravis patients. Autoimmunity. 2005;38:161-9.
75. Topham DJ, Nag B, Arimilli S, Sriram S. A synthetic peptide from the third hypervariable region of major histocompatibility complex class II β chain as a vaccine for treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 1994;91:8005-9.
76. Pera C, Delfino L, Longo A, Pistillo MP, Ferrara GB. Novel associations among HLA-DQA1 and -DQB1 alleles, revealed by high-resolution sequence-based typing (SBT). Tissue Antigens. 2000;55:275-9.
77. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens. 1993;41:119-34.
78. Nishimura Y, Kanai T, Oiso M, Tabata H, Ito H, Kira J, Chen YZ, Matsushita S. Molecular analysis of HLA class II-associated susceptibility to subtypes of autoimmune diseases unique to Asians. Int J Cardiol. 1998;66 Suppl 1:S93-S104.
79. Berman PW, Patrick J. Experimental myasthenia gravis. A murine system. J Exp Med. 1980;151:204-23.
80. Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid LM. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci U S A. 2004;101:4175-9.